Chief Accounting Officer
Dianthus Therapeutics, Inc. (DNTH)Equibles does not estimate personal net worth.
Get an email with a short summary when Dianthus Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DNTH alertsEdward Carr is recorded as Chief Accounting Officer at Dianthus Therapeutics, Inc. (DNTH) since September 11, 2023 and CFO at Abeona Therapeutics Inc. (ABEO) since August 10, 2021. The newest filing on record that lists Edward Carr as Chief Accounting Officer at Dianthus Therapeutics, Inc. (DNTH) is dated April 9, 2026. Dianthus Therapeutics, Inc. reported in an 8-K filed September 12, 2023 that Edward Carr was appointed Chief Accounting Officer and principal accounting officer, effective September 11, 2023. The proxy statement of Abeona Therapeutics Inc. reports total compensation of $1,569,879 for Edward Carr in fiscal 2021, including a base salary of $360,985. Disclosed compensation is on record for 2 fiscal years. Edward Carr has spoken on 5 earnings calls across 1 company, most recently for Abeona Therapeutics Inc. on November 15, 2021. Abeona Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Dianthus Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Abeona Therapeutics Inc. includes Michael Amoroso (CEO, Chairman, COO and Board Member), Vishwas Seshadri (CEO and Board Member), Brian J.G. Pereira (Chairman and Board Member) and 7 others.
“On September 11, 2023, the Board of Directors appointed Marino Garcia as the Company's President and Chief Executive Officer and principal executive officer, Ryan Savitz as the Company's Treasurer and Chief Financial Officer and principal financial officer and Edward Carr as the Company's Chief Accounting Officer and principal accounting officer.”
“I would like to remind everyone that the Form 10-Q is available on our website, which is where you can get additional details on our financial results for the 3 and 9 months ended September 30, 2021.”
“I would like to remind everyone that the Form 10-Q is available on our website, which is where you can get additional details on our financial results for the three and six months ended June 30, 2021.”
“I'd like to remind everyone that we have recently filed the Form 10-Q, which is available on our website and where you can get the details on our financial results.”
“I'd like to remind everyone that we have recently filed the Form 10-Q, which is available on our website and where you can get the details on our financial results.”
“I'd like to remind everyone that we have recently filed the Form 10-Q, where you can get all the specific details on our financial results. In summary, our cash, cash equivalents, and marketable securities as of March 31, 2020, were $116 million compared to $129 million as of December 31, 2019.”
2023-09-11–present
Last confirmed April 9, 2026
2021-08-10–present
Start not stated–2022-03-31
Biotechnology · Healthcare
CFO
2021-08-10–present
Biotechnology · Healthcare
Chief Accounting Officer
2023-09-11–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Abeona Therapeutics Inc. (ABEO) | Former Chief Accounting Officer and Chief Financial Officer | $360,985 | $1,569,879 |
| 2020 | Abeona Therapeutics Inc. (ABEO) | Former Chief Accounting Officer and Chief Financial Officer | $300,000 | $924,007 |
